-
2
-
-
0033014930
-
Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
-
Shipkova M, Armstrong VW, Wieland E et al: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol, 1999; 126(5): 1075-82
-
(1999)
Br J Pharmacol
, vol.126
, Issue.5
, pp. 1075-1082
-
-
Shipkova, M.1
Armstrong, V.W.2
Wieland, E.3
-
3
-
-
0035079669
-
Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes
-
Shipkova M, Strassburg CP, Braun F et al: Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol, 2001; 132: 1027-34
-
(2001)
Br J Pharmacol
, vol.132
, pp. 1027-1034
-
-
Shipkova, M.1
Strassburg, C.P.2
Braun, F.3
-
4
-
-
2442716361
-
Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats
-
Kobayashi M, Saitoh H, Kobayashi M et al: Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats. J Pharmacol Exper Ther, 2004; 309: 1029-35
-
(2004)
J Pharmacol Exper Ther
, vol.309
, pp. 1029-1035
-
-
Kobayashi, M.1
Saitoh, H.2
Kobayashi, M.3
-
5
-
-
0035189304
-
Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: Preliminary report
-
Shipkova M, Armstrong VW, Kuypers D et al: Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit, 2001; 23(6): 717-21
-
(2001)
Ther Drug Monit
, vol.23
, Issue.6
, pp. 717-721
-
-
Shipkova, M.1
Armstrong, V.W.2
Kuypers, D.3
-
6
-
-
0038298273
-
Longterm changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients
-
Kuypers DRJ, Claes K, Evenepoel P et al: Longterm changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol, 2003; 43(8): 866-80
-
(2003)
J Clin Pharmacol
, vol.43
, Issue.8
, pp. 866-880
-
-
Kuypers, D.R.J.1
Claes, K.2
Evenepoel, P.3
-
7
-
-
34547876119
-
The impact of renal allograft function on exposure and elimination of mycophenolic acid (mpa) and its metabolite mpa 7-o-glucuronide
-
Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR: The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. Transplantation, 2007; 84(3): 362-73
-
(2007)
Transplantation
, vol.84
, Issue.3
, pp. 362-373
-
-
Naesens, M.1
de Loor, H.2
Vanrenterghem, Y.3
Kuypers, D.R.4
-
8
-
-
2542590879
-
Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia
-
Atcheson B, Taylor P, Kirkpatrick C et al: Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit, 2004; 26(3): 284-86
-
(2004)
Ther Drug Monit
, vol.26
, Issue.3
, pp. 284-286
-
-
Atcheson, B.1
Taylor, P.2
Kirkpatrick, C.3
-
9
-
-
25844525727
-
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region singlenucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
-
Kuypers DRJ, Naesens M, Vermeire S et al: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region singlenucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther, 2005; 78: 351-61
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 351-361
-
-
Kuypers, D.R.J.1
Naesens, M.2
Vermeire, S.3
-
10
-
-
33750346955
-
Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients
-
Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y: Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients. Transplantation, 2006; 82(8): 1074-84
-
(2006)
Transplantation
, vol.82
, Issue.8
, pp. 1074-1084
-
-
Naesens, M.1
Kuypers, D.R.2
Verbeke, K.3
Vanrenterghem, Y.4
-
11
-
-
0030670814
-
Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
-
Zucker K, Rosen A, Tsaroucha A et al: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol, 1997; 5(3): 225-32
-
(1997)
Transplant Immunol
, vol.5
, Issue.3
, pp. 225-232
-
-
Zucker, K.1
Rosen, A.2
Tsaroucha, A.3
-
12
-
-
0035086852
-
Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
-
van Gelder T, Klupp J, Barten MJ et al: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit, 2001; 23(2): 119-28
-
(2001)
Ther Drug Monit
, vol.23
, Issue.2
, pp. 119-128
-
-
van Gelder, T.1
Klupp, J.2
Barten, M.J.3
-
13
-
-
17644377916
-
Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2
-
Hesselink DA, van Hest RM, Mathot RAA et al: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am Journal Transplant, 2005; 5(5): 987-95
-
(2005)
Am Journal Transplant
, vol.5
, Issue.5
, pp. 987-995
-
-
Hesselink, D.A.1
van Hest, R.M.2
Mathot, R.A.A.3
-
14
-
-
31444448077
-
Role of Mrp2 in the hepatic disposition of mycophenolic acid: Effect of cyclosporin
-
Westley IS, Brogan LR, Morris RG et al: Role of Mrp2 in the hepatic disposition of mycophenolic acid: effect of cyclosporin. Drug Metab Dispos, 2006; 34(2): 261-266
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.2
, pp. 261-266
-
-
Westley, I.S.1
Brogan, L.R.2
Morris, R.G.3
-
15
-
-
22244431879
-
Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium
-
Bruce Kaplan, Herwig-Ulf Meier-Kriesche, Paula Minnick, Marie-Claude Bastien, Romain Sechaud, Ching-Ming Yeh, Sebastien Balez, Franck Picard, Robert Schmouder: Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant, 2005; 19(4): 551-558
-
(2005)
Clin Transplant
, vol.19
, Issue.4
, pp. 551-558
-
-
Kaplan, B.1
Meier-Kriesche, H.-U.2
Minnick, P.3
Marie-Claude, B.4
Sechaud, R.5
Ching-Ming, Y.6
Balez, S.7
Picard, F.8
Schmouder, R.9
-
16
-
-
77956281242
-
Pharmacokinetics of mycophenolate mofetil at 12 months in the presence and absence of cyclosporine
-
(Abstract)
-
DRJ Kuypers, H Ekberg, J Grinyo et al: Pharmacokinetics of mycophenolate mofetil at 12 months in the presence and absence of cyclosporine. Transplant Int, 2005; 18(Suppl.1): 50 (Abstract)
-
(2005)
Transplant Int
, vol.18
, Issue.SUPPL. 1
, pp. 50
-
-
Kuypers, D.R.J.1
Ekberg, H.2
Grinyo, J.3
-
17
-
-
33745957413
-
Therapeutic drug monitoring of mycophenolate mofetil in transplantation
-
van Gelder T, Le Meur Y, Shaw LM et al: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit, 2006; 28: 145-54
-
(2006)
Ther Drug Monit
, vol.28
, pp. 145-154
-
-
van Gelder, T.1
Le, M.Y.2
Shaw, L.M.3
-
18
-
-
35248860066
-
For the FDCC Study Group: A prospective, randomized study comparing fixed dose versus concentration controlled MMF regimens for de novo patients following renal transplantation (The FDCC trial)
-
(Abstract)
-
van Gelder T, Tedesco-Silva H, de Fijter H et al: for the FDCC Study Group: A prospective, randomized study comparing fi xed dose versus concentration controlled MMF regimens for de novo patients following renal transplantation (The FDCC trial). Am J Transplant, 2006; 6(Suppl.2): 343 (Abstract)
-
(2006)
Am J Transplant
, vol.6
, Issue.SUPPL. 2
, pp. 343
-
-
van Gelder, T.1
Tedesco-Silva, H.2
de Fijter, H.3
et al4
-
19
-
-
36249004730
-
Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy
-
(Abstract)
-
Grinyo J, Ekberg H, Oppenheimer F et al: Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy. Am J Transplant, 2006; 6(Suppl.2): 345 (Abstract)
-
(2006)
Am J Transplant
, vol.6
, Issue.SUPPL. 2
, pp. 345
-
-
Grinyo, J.1
Ekberg, H.2
Oppenheimer, F.3
-
20
-
-
35248839494
-
Individualized mycophenolate mofetil dosing based on drug exposure signifi cantly improves patient outcomes after renal transplantation
-
Le Meur Y, Büchler M, Thierry A et al: Individualized mycophenolate mofetil dosing based on drug exposure signifi cantly improves patient outcomes after renal transplantation. Am J Transplant, 2007; 7: 2496-503
-
(2007)
Am J Transplant
, vol.7
, pp. 2496-2503
-
-
Le, M.Y.1
Büchler, M.2
Thierry, A.3
-
21
-
-
0033023263
-
Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
-
Zucker K, Tsaroucha A, Olson L et al: Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit, 1999; 21: 35-43
-
(1999)
Ther Drug Monit
, vol.21
, pp. 35-43
-
-
Zucker, K.1
Tsaroucha, A.2
Olson, L.3
-
22
-
-
33644824716
-
Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation
-
Cattaneo D, Merlini S, Zenoni S et al: Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. Am J Transplant, 2005; 5(12): 2937-44
-
(2005)
Am J Transplant
, vol.5
, Issue.12
, pp. 2937-2944
-
-
Cattaneo, D.1
Merlini, S.2
Zenoni, S.3
-
23
-
-
36849071973
-
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients
-
Pescovitz MD, Vincenti F, Hart M et al: Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol, 2007; 64(6): 758-71
-
(2007)
Br J Clin Pharmacol
, vol.64
, Issue.6
, pp. 758-771
-
-
Pescovitz, M.D.1
Vincenti, F.2
Hart, M.3
-
24
-
-
4344686731
-
Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs
-
Renders L, Steinbach R, Valerius T et al: Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res, 2004; 27(3): 181-85
-
(2004)
Kidney Blood Press Res
, vol.27
, Issue.3
, pp. 181-185
-
-
Renders, L.1
Steinbach, R.2
Valerius, T.3
-
25
-
-
0036424769
-
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
-
Cattaneo D, Perico N, Gaspari F et al: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int, 2002; 62(3): 1060-67
-
(2002)
Kidney Int
, vol.62
, Issue.3
, pp. 1060-1067
-
-
Cattaneo, D.1
Perico, N.2
Gaspari, F.3
-
26
-
-
0029827815
-
Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
-
Stepkowski SM, Napoli KL, Wang ME et al: Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation, 1996; 62(7): 986-94
-
(1996)
Transplantation
, vol.62
, Issue.7
, pp. 986-994
-
-
Stepkowski, S.M.1
Napoli, K.L.2
Wang, M.E.3
-
27
-
-
0035042276
-
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations
-
Podder H, Stepkowski SM, Napoli KL et al: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol, 2001; 12: 1059-71
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 1059-1071
-
-
Podder, H.1
Stepkowski, S.M.2
Napoli, K.L.3
-
28
-
-
0031958040
-
Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration in the rat: Evidence for pharmacokinetic interactions
-
Napoli KL, Wang ME, Stepkowski SM et al: Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration in the rat: evidence for pharmacokinetic interactions. Ther Drug Monit, 1998; 20(2): 123-33
-
(1998)
Ther Drug Monit
, vol.20
, Issue.2
, pp. 123-133
-
-
Napoli, K.L.1
Wang, M.E.2
Stepkowski, S.M.3
-
29
-
-
33746530366
-
The Rapamune US Study Group: Efficacy of sirolimus compare with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
-
Kahan BD The Rapamune US Study Group: Efficacy of sirolimus compare with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet, 2000; 356: 194-202
-
(2000)
Lancet
, vol.356
, pp. 194-202
-
-
Kahan, B.D.1
-
30
-
-
0035956745
-
The RAPAMUNE Global Study Group: A worldwide, phase III, randomised, controlled, safety and effi cacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
-
MacDonald AS The RAPAMUNE Global Study Group: A worldwide, phase III, randomised, controlled, safety and effi cacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation, 2001; 71(2): 271-80
-
(2001)
Transplantation
, vol.71
, Issue.2
, pp. 271-280
-
-
MacDonald, A.S.1
-
31
-
-
3943072739
-
156 Study Group: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, openlabel study
-
Nashan B, Curtis J, Ponticelli C et al: 156 Study Group: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, openlabel study. Transplantation, 2004; 78(9): 1332-40
-
(2004)
Transplantation
, vol.78
, Issue.9
, pp. 1332-1340
-
-
Nashan, B.1
Curtis, J.2
Ponticelli, C.3
-
32
-
-
0037961745
-
Fixed-dose sirolimus with reduced dose calcineurin inhibitor: The university of Colorado experience
-
Wiseman AC, Kam I, Christians U et al: Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the university of Colorado experience. Transplant Proc, 2003; 35(Suppl.3A): 122S-24S
-
(2003)
Transplant Proc
, vol.35
, Issue.SUPPL. 3A
, pp. 122-124
-
-
Wiseman, A.C.1
Kam, I.2
Christians, U.3
-
33
-
-
0033567982
-
Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
-
Hong JC, Kahan BD: Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation, 1999; 68(5): 701-4
-
(1999)
Transplantation
, vol.68
, Issue.5
, pp. 701-704
-
-
Hong, J.C.1
Kahan, B.D.2
-
34
-
-
0036901716
-
Basiliximabsirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors
-
Langer RM, Hong DM, Katz SM et al: Basiliximabsirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors. Transplant Proc, 2002; 34: 3162-64
-
(2002)
Transplant Proc
, vol.34
, pp. 3162-3164
-
-
Langer, R.M.1
Hong, D.M.2
Katz, S.M.3
-
35
-
-
0035884710
-
Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure
-
Johnson RW, Kreis H, Oberbauer R et al: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation, 2001; 72(5): 777-86
-
(2001)
Transplantation
, vol.72
, Issue.5
, pp. 777-786
-
-
Johnson, R.W.1
Kreis, H.2
Oberbauer, R.3
-
36
-
-
16244378141
-
The B251 Study Group: Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study
-
Lorber M, Mulgaonkar S, Butt KMH et al: the B251 Study Group: Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study. Transplantation, 2005; 80(2): 244-52
-
(2005)
Transplantation
, vol.80
, Issue.2
, pp. 244-252
-
-
Lorber, M.1
Mulgaonkar, S.2
Butt, K.M.H.3
-
37
-
-
33644696712
-
For the RAD B201 Study Group: Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients
-
Vítko Š, Margreiter R, Weimar W et al: for the RAD B201 Study Group: Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients. Am J Transplant, 2005; 5(10): 2521-30
-
(2005)
Am J Transplant
, vol.5
, Issue.10
, pp. 2521-2530
-
-
Vítko, S.1
Margreiter, R.2
Weimar, W.3
-
38
-
-
5644239801
-
Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats
-
Konishi H, Sumi M, Shibata N et al: Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharmacy Pharmacol, 2004; 56: 1259-66
-
(2004)
J Pharmacy Pharmacol
, vol.56
, pp. 1259-1266
-
-
Konishi, H.1
Sumi, M.2
Shibata, N.3
-
39
-
-
33748539303
-
Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporine A absorption, and effect of dexamethasone in small intestine of mice
-
Jin M, Shimada T, Yokogawa K et al: Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporine A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol, 2006; 72(8): 1042-50
-
(2006)
Biochem Pharmacol
, vol.72
, Issue.8
, pp. 1042-1050
-
-
Jin, M.1
Shimada, T.2
Yokogawa, K.3
-
40
-
-
0242558148
-
Increase in tacrolimus trough levels after steroid withdrawal
-
van Duijnhoven EM et al: Increase in tacrolimus trough levels after steroid withdrawal. Transplant Int, 2003; 16: 721-25
-
(2003)
Transplant Int
, vol.16
, pp. 721-725
-
-
van Duijnhoven, E.M.1
-
41
-
-
0041317355
-
Tacrolimus dose requirement in renal transplant recipients is signifi cantly higher when used in combination with corticosteroids
-
Hesselink DA, Ngyuen H, Wabbijn M et al: Tacrolimus dose requirement in renal transplant recipients is signifi cantly higher when used in combination with corticosteroids. Br J Clin Pharmacol, 2003; 56(3): 327-30
-
(2003)
Br J Clin Pharmacol
, vol.56
, Issue.3
, pp. 327-330
-
-
Hesselink, D.A.1
Ngyuen, H.2
Wabbijn, M.3
-
42
-
-
0036851317
-
Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after highdose steroid therapy
-
Shimada T et al: Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after highdose steroid therapy. Transplantation, 2002; 74: 1419-24
-
(2002)
Transplantation
, vol.74
, pp. 1419-1424
-
-
Shimada, T.1
-
43
-
-
47949092525
-
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans
-
Epub ahead of print
-
Roberts P, Rollins K, Kashuba A et al: The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos, 2008; Epub ahead of print
-
(2008)
Drug Metab Dispos
-
-
Roberts, P.1
Rollins, K.2
Kashuba, A.3
-
44
-
-
0036001229
-
A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration
-
McAlister VC, Mahalati K, Peltekian KM et al: A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit, 2002; 24: 346-50
-
(2002)
Ther Drug Monit
, vol.24
, pp. 346-350
-
-
McAlister, V.C.1
Mahalati, K.2
Peltekian, K.M.3
-
45
-
-
0042266823
-
Longterm pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients
-
Kuypers DRJ, Claes K, Evenepoel P et al: Longterm pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit, 2003; 25(4): 447-51
-
(2003)
Ther Drug Monit
, vol.25
, Issue.4
, pp. 447-451
-
-
Kuypers, D.R.J.1
Claes, K.2
Evenepoel, P.3
-
46
-
-
0038684549
-
Pharmacokinetics of tacrolimus-based combination therapies
-
Undre NA: Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant, 2003; 18(Suppl.1): 12-15
-
(2003)
Nephrol Dial Transplant
, vol.18
, Issue.SUPPL. 1
, pp. 12-15
-
-
Undre, N.A.1
-
47
-
-
38549132528
-
Everolimus exposure in cardiac transplant recipients is infl uenced by concomitant alcineurin inhibitor
-
Brandhorst G, Tenderich G, Zittermann A et al: Everolimus exposure in cardiac transplant recipients is infl uenced by concomitant alcineurin inhibitor. Ther Drug Monit, 2008; 30(1): 113-16
-
(2008)
Ther Drug Monit
, vol.30
, Issue.1
, pp. 113-116
-
-
Brandhorst, G.1
Tenderich, G.2
Zittermann, A.3
-
48
-
-
10744220677
-
A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year
-
Ciancio G, Burke GW, Gaynor JJ et al: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation, 2004; 77(2): 244-51
-
(2004)
Transplantation
, vol.77
, Issue.2
, pp. 244-251
-
-
Ciancio, G.1
Burke, G.W.2
Gaynor, J.J.3
-
49
-
-
18044379147
-
Effects of calcineurininhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients
-
Wu F, Tsai M, Chen R et al: Effects of calcineurininhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy, 2005; 25(5): 646-53
-
(2005)
Pharmacotherapy
, vol.25
, Issue.5
, pp. 646-653
-
-
Wu, F.1
Tsai, M.2
Chen, R.3
-
50
-
-
0030477754
-
Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants
-
Jusko W, Ferron G, Mis S et al: Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol, 1996; 36(12): 1100-1106
-
(1996)
J Clin Pharmacol
, vol.36
, Issue.12
, pp. 1100-1106
-
-
Jusko, W.1
Ferron, G.2
Mis, S.3
|